Article

Lars Andersson, PhD: Identifying Mediators in Asthma and COPD Patients

Author(s):

Obese-related asthma is considered one of the more severe asthma phenotypes.

It has become increasingly important to consider the influence of sex and age on adipokine biomarkers for obese-related asthma.

Recently, in a paper presented at the European Respiratory Society International Congress 2020 (ERS 2020), researchers found adiponectin and leptin were significantly different between men and women, with higher levels found in female patients.

The researchers found inflamed adipose tissue releases adipokines with metabolic, pro- or anti-inflammatory activities ultimately contributing to the pathophysiology. A similar role of adipokines in COPD disease pathway has been proposed.

However, the impact of sex and age on circulating adipokines was previously unclear.

In the study, the team, led by Lars L. Andersson, PhD, Karolinska Institute, examined the influence of sex and age on plasma levels of 9 adipokines.

The study included 55 patients with mild to moderate asthma, 72 patients with severe asthma, and 41 patients with COPD. Overall, the researchers found both adiponectin and leptin were highly affected by body mass index (BMI).

In a subgroup analysis, they found the difference in adiponectin between women and men was smaller in lean patients, while the difference in leptin was smaller in obese patients.

In an interview with HCPLive®, Andersson explained how the study could result in better patient care.

Related Videos
New Buprenorphine Label Allows Physician-Informed Treatment of Opioid Use Disorder, with Bobby Mukkamala, MD
Jonathan Stine, MD, MSc | Credit: AASLD
Christina Druskovich: A Mentorship Opportunity with the Society for Pediatric Dermatology
Evaluating the Medtronic 780G System in Type 2 Diabetes | Image Credit: HCPLive
Understanding Omnipod 5 AID and SECURE-T2D | Image Credit: HCPLive
After the Smoke: Wildfire Cleanup & Air Quality Concerns with Afif El-Hasan, MD
Atopic Disease Hypersensitivity Reactions Vary by Biologic Type with Valerie Jaroenpuntaruk, MD
The Evolving Use of Biologics for PsA Care, with Philip Mease, MD
Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD
© 2025 MJH Life Sciences

All rights reserved.